Indication
Treatment of moderate-to-severe atopic dermatitis (AD) in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.
Medicine details
- Medicine name:
- nemolizumab (Nemluvio)
- SMC ID:
- SMC2833
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC